PhaseBio Pharmaceuticals, Inc. announced that Jonathan P. Mow has been appointed Chief Business Officer. Mr. Mow has more than 20 years of experience in business development and commercial operations, most recently with Amylin Pharmaceuticals, where he implemented the strategy that resulted in Amylin's $7 billion acquisition by Bristol-Myers Squibb and Astra Zeneca. Prior to joining PhaseBio, Mr. Mow was Vice President, Business Development, for Amylin Pharmaceuticals, where he was responsible for business development and strategic planning resulting in completion of numerous transactions.

Notably, Mr. Mow was responsible for implementing a partnership with Takeda for the treatment of obesity through a multi-asset development and commercialization collaboration.